These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 38376947)
1. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis. Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947 [TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation. Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina. Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946 [TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada. Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046 [TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225 [TBL] [Abstract][Full Text] [Related]
7. Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis. Amani B; Amani B Expert Rev Anti Infect Ther; 2024 Jul; 22(7):547-555. PubMed ID: 38457124 [TBL] [Abstract][Full Text] [Related]
8. Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis. Okoli GN; Askin N; Rabbani R Ann Fam Med; 2024; 22(4):336-346. PubMed ID: 39038972 [TBL] [Abstract][Full Text] [Related]
9. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM; N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054 [TBL] [Abstract][Full Text] [Related]
10. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19. Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Hagen MB; Gerhart JL Clin Infect Dis; 2024 Jul; 79(1):108-110. PubMed ID: 38411622 [TBL] [Abstract][Full Text] [Related]
11. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790 [TBL] [Abstract][Full Text] [Related]
12. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies. Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents. Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991 [TBL] [Abstract][Full Text] [Related]
14. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study. Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461 [TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. Tian F; Chen Z; Feng Q J Med Virol; 2023 Apr; 95(4):e28732. PubMed ID: 37183808 [TBL] [Abstract][Full Text] [Related]
16. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease. Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis. Zur M; Peselev T; Yanko S; Rotshild V; Matok I Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602 [TBL] [Abstract][Full Text] [Related]
18. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related]
19. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes. Chagla Z Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374 [TBL] [Abstract][Full Text] [Related]
20. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system. Malden DE; McLaughlin JM; Hong V; Lewnard J; Ackerson BK; Puzniak L; Kim JS; Takhar H; Frankland TB; Slezak JM; Tartof SY Sci Rep; 2024 Mar; 14(1):7485. PubMed ID: 38553527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]